What healthcare & life sciences sourcing teams are up against
-
01Rising R&D and clinical trial costs Vendor costs for clinical trial sites, CROs, and specialized lab services continue climbing, often without clear market benchmarks.
-
02Supplier compliance and quality requirements GMP compliance, regulatory audit history, and quality certifications must be verified before a supplier is qualified, not just checked as a formality.
-
03Pricing scrutiny Drug and device pricing faces continuous regulatory and payer pressure, which flows back into how aggressively input costs need to be managed.
-
04Concentrated, specialized supplier markets Key inputs (APIs, biologics, specialized components) often come from a small number of qualified global suppliers, limiting negotiating leverage without strong market intelligence.
Three services, applied to Healthcare & Life Sciences
Category Intelligence & Reports →
Deep, current reporting on specialized categories (APIs, biologics, clinical trial services) where generic industry reports fall short.
Cost Modelling →
Should-cost and TCO models for specialized inputs, giving sourcing teams a benchmark in categories with limited supplier competition.
Procurement Intelligence & Supplier Selection →
Compliance-focused due diligence for suppliers in GMP-regulated categories.
Built for the teams making the call
Category managers for clinical and lab supplies, life sciences sourcing leaders, and R&D procurement teams managing specialized, compliance-heavy categories.
Common questions
Can you assess supplier GMP compliance as part of due diligence?+
Yes, compliance and quality certification history is a core part of our due diligence work for regulated healthcare and life sciences categories.
How do you build cost benchmarks in categories with only a handful of qualified global suppliers?+
We combine bottom-up cost modeling (materials, regulatory overhead, capacity constraints) with whatever market pricing signals exist, since a concentrated supplier base means less public pricing data is available than in commoditized categories.